21 CFR 316.4 - Address for submissions.
All correspondence and requests for FDA action under the provisions of this rule should be addressed as follows: Office of Orphan Products Development, Food and Drug Administration, Bldg. 32, Rm. 5271, 10903 New Hampshire Ave., Silver Spring, MD 20993.
Title 21 published on 2015-12-03.
No entries appear in the Federal Register after this date, for 21 CFR Part 316.